PLCγ2 deficiency induces greater tumor growth and MDSC accumulation. (A and B) 10⁵ B16 melanoma (A) or LLC (B) cells were s.c. injected into PLCγ2^−/− or WT mice and tumor growth was evaluated for 14 d. Percentage of MDSCs in the bone marrow, spleen, and tumor site was analyzed by FACS using anti–Gr-1 and CD11b staining. Results represent mean ± SD (B16: n = 5, experiment done in duplicate; LLC: n = 3, experiment repeated 4 times). *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) 10⁵ LLC cells were s.c. injected in PLCγ2^−/− or WT mice. 7 d after tumor challenge, the tumor was resected and weighed. Percentage of MDSCs from bone marrow, spleen and tumor were then analyzed by FACS staining (Gr-1⁺CD11b⁺, MDSCs). Results represent mean ± SD (n = 4). Data are reported from one of two similar independent experiments. **, P < 0.01.